User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Treatment of chronic hepatitis C in elderly patients

Primary tabs

Horsmans, Yves [UCL]

Importance of the field: The issue of age in cases of chronic hepatitis C (HCV) in the West is a major problem; the average age of patients with HCV is increasing and its prevalence increases with advancing age. Areas covered in this review: This review is devoted to the analysis of the limited number of clinical studies performed to treat HCV in elderly patients. What the reader will gain: The importance of the age factor is outlined in nearly all the studies done in the field. Advanced age is associated with a lower sustained virologic response (SVR) rate. Moreover, in elderly patients, these studies also tend to suggest that, before initiating an antiviral treatment, the physician should not only take into account the classical parameters associated with SVR but also the presence of co-morbidities and life expectancy. Take-home messages: Antiviral therapy should be used in selected elderly HCV patients with advanced fibrosis and more studies are required in this population to better define the parameters associated with SVR. As age is an important factor in the success of antiviral therapy, starting antiviral treatment at a young age should be favored.

Document type Article de périodique (Journal article) – Synthèse de littérature – Journal Article, Review
Publication date 2010
Language Anglais
Journal information "Expert Opinion on Pharmacotherapy" - Vol. 11, no. 4, p. 571-577 (2010)
Peer reviewed yes
Publisher Informa Healthcare ((United Kingdom) London)
issn 1465-6566
e-issn 1744-7666
Publication status Publié
Affiliations UCL - SSS/IREC/ECLI - Pôle d'Essais cliniques
UCL - (SLuc) Service d'hépato-gastro-entérologie
MESH Subject Treatment Outcome ; Middle Aged ; Life Expectancy ; Humans ; Hepatitis C, Chronic - drug therapy - economics - epidemiology ; Health Care Costs ; Drug Therapy, Combination ; Comorbidity ; Clinical Trials as Topic ; Antiviral Agents - economics - therapeutic use ; Aged ; Age Factors
Links
  1. Manns Michael P, McHutchison John G, Gordon Stuart C, Rustgi Vinod K, Shiffman Mitchell, Reindollar Robert, Goodman Zachary D, Koury Kenneth, Ling Mei-Hsiu, Albrecht Janice K, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, 10.1016/s0140-6736(01)06102-5
  2. Fried Michael W., Shiffman Mitchell L., Reddy K. Rajender, Smith Coleman, Marinos George, Gonçales Fernando L., Häussinger Dieter, Diago Moises, Carosi Giampiero, Dhumeaux Daniel, Craxi Antonio, Lin Amy, Hoffman Joseph, Yu Jian, Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection, 10.1056/nejmoa020047
  3. Hadziyannis Stephanos J., Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C : A Randomized Study of Treatment Duration and Ribavirin Dose, 10.7326/0003-4819-140-5-200403020-00010
  4. Armstrong Gregory L., Wasley Annemarie, Simard Edgar P., McQuillan Geraldine M., Kuhnert Wendi L., Alter Miriam J., The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002, 10.7326/0003-4819-144-10-200605160-00004
  5. McHutchinson JG, Am J Manag Care, 11, S286 (2005)
  6. Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili L A, Menniti-Ippolito F, Caroleo B, Costa C, Griffo G, Loiacono L, Pisani V, Foca A, Piazza M, Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy, 10.1002/hep.510260431
  7. Sagnelli Evangelista, Stroffolini Tommaso, Mele Alfonso, Almasio Piero, Coppola Nicola, Ferrigno Luigina, Scolastico Carlo, Onofrio Mirella, Imparato Michele, Filippini Pietro, , The importance of HCV on the burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases, 10.1002/jmv.20313
  8. Gordon Stuart C., Elloway Richard S., Long John C., Dmuchowski Carl F., The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs. Intravenous drug use, 10.1002/hep.1840180609
  9. Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M, Epidemiology and long term prognosis of hepatitis C virus infection in Japan., 10.1136/gut.34.2_suppl.s13
  10. Poynard Thierry, Bedossa Pierre, Opolon Pierre, Natural history of liver fibrosis progression in patients with chronic hepatitis C, 10.1016/s0140-6736(96)07642-8
  11. Seeff Leonard B., The history of the “natural history” of hepatitis C (1968-2009), 10.1111/j.1478-3231.2008.01927.x
  12. Floreani A., Bertin T., Soffiati G., Naccarato R., Chiaramonte M., Anti-Hepatitis C Virus in the Elderly: A Seroepidemiological Study in a Home for the Aged, 10.1159/000213330
  13. Solana Rafael, Pawelec Graham, Molecular and cellular basis of immunosenescence, 10.1016/s0047-6374(98)00029-3
  14. Linton Phyllis Jean, Dorshkind Kenneth, Age-related changes in lymphocyte development and function, 10.1038/ni1033
  15. Rehermann Barbara, Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence, 10.1172/jci39133
  16. Hoare Matthew, Gelson William T. H., Rushbrook Simon M., Curran Martin D., Woodall Tracy, Coleman Nicholas, Davies Susan E., Alexander Graeme J. M., Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection, 10.1002/hep.22484
  17. Fargnoli J., Kunisada T., Fornace A. J., Schneider E. L., Holbrook N. J., Decreased expression of heat shock protein 70 mRNA and protein after heat treatment in cells of aged rats., 10.1073/pnas.87.2.846
  18. Zhang H. J., Chronic antioxidant enzyme mimetic treatment differentially modulates hyperthermia-induced liver HSP70 expression with aging, 10.1152/japplphysiol.01046.2005
  19. Ratziu V, Hepatology, 32, 302A (2000)
  20. Krizhanovsky Valery, Yon Monica, Dickins Ross A., Hearn Stephen, Simon Janelle, Miething Cornelius, Yee Herman, Zender Lars, Lowe Scott W., Senescence of Activated Stellate Cells Limits Liver Fibrosis, 10.1016/j.cell.2008.06.049
  21. Bresci Giampaolo, Del Corso Laura, Romanelli Anna Maria, Giuliano Gabriella, Pentimone Ferdinando, The Use of Recombinant Interferon Alfa-2b in Elderly Patients with Anti-HCV-Positive Chronic Active Hepatitis, 10.1111/j.1532-5415.1993.tb06184.x
  22. Imai Yasuharu, Kasahara Akinori, Tanaka Hideo, Okanoue Takeshi, Hiramatsu Naoki, Tsubouchi Hirohito, Yoshioka Kentaro, Kawata Sumio, Tanaka Eiji, Hino Keisuke, Hayashi Katsuhiro, Tamura Shinji, Itoh Yoshito, Sasaki Yutaka, Kiyosawa Kendo, Kakumu Shinichi, Okita Kiwamu, Hayashi Norio, Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response, 10.1007/s00535-004-1448-0
  23. HORIIKE NORIO, MASUMOTO TOSHIKAZU, NAKANISHI KIMIO, MICHITAKA KOJIRO, KUROSE KIYOTAKA, OHKURA IZUMI, ONJI MORIKAZU, Interferon therapy for patients more than 60 years of age with chronic hepatitis C, 10.1111/j.1440-1746.1995.tb01088.x
  24. Alessi N, Infez Med, 11, 208 (2003)
  25. Arase Yasuji, Ikeda Kenji, Suzuki Fumitaka, Suzuki Yoshiyuki, Saitoh Satoshi, Kobayashi Masahiro, Akuta Norio, Someya Takashi, Koyama Rikako, Hosaka Tetsuya, Sezaki Hitomi, Kobayashi Mariko, Kumada Hiromitsu, Long-Term Outcome after Interferon Therapy in Elderly Patients with Chronic Hepatitis C, 10.1159/000096308
  26. Ikeda Kenji, Arase Yasuji, Kawamura Yusuke, Yatsuji Hiromi, Sezaki Hitomi, Hosaka Tetsuya, Akuta Norio, Kobayashi Masahiro, Saitoh Satoshi, Suzuki Fumitaka, Suzuki Yoshiyuki, Kumada Hiromitsu, Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C, 10.1016/j.amjmed.2008.09.045
  27. Thabut Dominique, Le Calvez Sophie, Thibault Vincent, Massard Julien, Munteanu Mona, Di Martino Vincent, Ratziu Vlad, Poynard Thierry, Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease?, 10.1111/j.1572-0241.2006.00556.x
  28. Iwasaki Yoshiaki, Ikeda Hiroshi, Araki Yasuyuki, Osawa Toshiya, Kita Keiji, Ando Masaharu, Shimoe Toshinari, Takaguchi Kouichi, Hashimoto Noriaki, Kobatake Toshitsugu, Tomita Minoru, Kawaguchi Mitsuhiko, Kobashi Haruhiko, Sakaguchi Kohsaku, Shiratori Yasushi, Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C, 10.1002/hep.20984
  29. Hiramatsu N, Hepatol Res, 35, 185 (2006)
  30. Koyama Rikako, Arase Yasuji, Ikeda Kenji, Suzuki Fumitaka, Suzuki Yoshiyuki, Saitoh Satoshi, Kobayashi Masahiro, Akuta Norio, Someya Takashi, Hosaka Tetsuya, Sezaki Hitomi, Kobayashi Mariko, Kumada Hiromitsu, Efficacy of Interferon Therapy in Elderly Patients with Chronic Hepatitis C, 10.1159/000089372
  31. Kumada Takashi, Toyoda Hidenori, Honda Takashi, Kuzuya Teiji, Katano Yosiaki, Nakano Isao, Goto Hidemi, Treatment of Chronic Hepatitis C with Interferon Alone or Combined with Ribavirin in Japan, 10.1159/000087273
  32. Honda Takashi, Katano Yoshiaki, Urano Fumihiro, Murayama Mutsumi, Hayashi Kazuhiko, Ishigami Masatoshi, Nakano Isao, Yoshioka Kentaro, Toyoda Hidenori, Kumada Takashi, Goto Hidemi, Efficacy of ribavirin plus interferon-? in patients aged ?60�years with chronic hepatitis C, 10.1111/j.1440-1746.2006.04773.x
  33. Floreani Annarosa, Minola Eliseo, Carderi Isabella, Ferrara Francesco, Rizzotto Erik Rosa, Baldo Vincenzo, ARE ELDERLY PATIENTS POOR CANDIDATES FOR PEGYLATED INTERFERON PLUS RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C? : LETTERS TO THE EDITOR, 10.1111/j.1532-5415.2006.00643_4.x
  34. Antonucci Giorgio, Longo Maria Antonella, Angeletti Claudio, Vairo Francesco, Oliva Alessandra, Comandini Ubaldo Visco, Tocci Guido, Boumis Evangelo, Noto Pasquale, Solmone Maria Carmela, Capobianchi Maria R., Girardi Enrico, The Effect of Age on Response to Therapy With Peginterferon ? Plus Ribavirin in a Cohort of Patients With Chronic HCV Hepatitis Including Subjects Older Than 65 Yr, 10.1111/j.1572-0241.2007.01201.x
  35. Puoti M, J Hepatol, 48, S309 (2008)
  36. Dai C.-Y., Huang C.-F., Yu M.-L., Huang J.-F., Chuang W.-L., 617 EFFICACY AND SAFETY OF PEGYLATED INTERFERON- ALPHA PLUS RIBAVIRIN COMBINATION THERAPY IN OLD AGE CHRONIC HEPATITIS C PATIENTS, 10.1016/s0168-8278(09)60619-x
  37. Sezaki Hitomi, Suzuki Fumitaka, Kawamura Yusuke, Yatsuji Hiromi, Hosaka Tetsuya, Akuta Norio, Kobayashi Masahiro, Suzuki Yoshiyuki, Saitoh Satoshi, Arase Yasuji, Ikeda Kenji, Miyakawa Yuzo, Kumada Hiromitsu, Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads, 10.1007/s10620-008-0500-y
  38. Honda T, Liver Int (2009)
  39. Reddy K. R., Messinger D., Popescu M., Hadziyannis S. J., Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients, 10.1111/j.1365-2893.2009.01122.x
  40. Yoshida Haruhiko, Shiratori Yasushi, Moriyama Mitsuhiko, Arakawa Yasuyuki, Ide Tatsuya, Sata Michio, Inoue Osami, Yano Michitami, Tanaka Motohiko, Fujiyama Shigetoshi, Nishiguchi Shuhei, Kuroki Tetsuo, Imazeki Fumio, Yokosuka Osamu, Kinoyama Shingo, Yamada Gotaro, Omata Masao, , Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan, 10.7326/0003-4819-131-3-199908030-00003
  41. Asahina Y., Izuni N., Hirayama I., Sato M., Yasui Y., Tanaka T., Komatsu N., Umeda N., Hosokawa T., Ueda K., Tsuchiya K., Nakanishi H., Itakura J., Kurosaki M., Miyake S., 13 POTENTIAL NEGATIVE IMPACT OF AGING ON HEPATOCARCINOGENESIS AFTER ANTI-VIRAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C AND BENEFIT OF VIRAL ERADICATION BY PEG-INTERFRON/RIBAVIRIN TREATMENT, 10.1016/s0168-8278(08)60015-x
  42. Veldt Bart J., Heathcote E. Jenny, Wedemeyer Heiner, Reichen Juerg, Hofmann W. Peter, Zeuzem Stefan, Manns Michael P., Hansen Bettina E., Schalm Solko W., Janssen Harry L.A., Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis, 10.7326/0003-4819-147-10-200711200-00003
  43. Salomon Joshua A., Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population, 10.1001/jama.290.2.228
  44. Gerkens S., Nechelput M., Annemans L., Peraux B., Mouchart M., Beguin C., Horsmans Y., A health economic model to assess the cost-effectiveness of PEG IFN ?-2a and ribavirin in patients with mild chronic hepatitis C, 10.1111/j.1365-2893.2006.00831.x
  45. Gerkens S, Acta Gastroenterol Belg, 70, 177 (2007)
  46. Neumann Avidan U., Pianko Stephen, Zeuzem Stefan, Yoshida Eric M., Benhamou Yves, Mishan Moshe, McHutchison John G., Pulkstenis Erik, Mani Subramanian G., Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C, 10.1016/j.jhep.2009.01.017
  47. Martinot-Peignoux M, Antivir Ther, 14, 501 (2009)
  48. Thompson A. J. V., McHutchison J. G., Antiviral resistance and specifically targeted therapy for HCV (STAT-C), 10.1111/j.1365-2893.2009.01124.x
Bibliographic reference Horsmans, Yves. Treatment of chronic hepatitis C in elderly patients. In: Expert Opinion on Pharmacotherapy, Vol. 11, no. 4, p. 571-577 (2010)
Permanent URL http://hdl.handle.net/2078.1/29680